A Phase II Trial of Abiraterone Acetate, Radiotherapy and Short-Term Androgen Deprivation in Men With Unfavorable Risk Localized Prostate Cancer
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 16 May 2017
At a glance
- Drugs Abiraterone acetate (Primary) ; Goserelin; Leuprorelin; Prednisone
- Indications Prostate cancer
- Focus Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 09 May 2017 Planned End Date changed from 1 Sep 2018 to 1 Sep 2021.
- 12 Sep 2016 Status changed from recruiting to active, no longer recruiting.